A5071944022- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Cancer Research and Treatments
- Viral-associated cancers and disorders
- Nanowire Synthesis and Applications
- Head and Neck Cancer Studies
- Metastasis and carcinoma case studies
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Glycosylation and Glycoproteins Research
- Nanofabrication and Lithography Techniques
- Esophageal Cancer Research and Treatment
- Advanced Biosensing Techniques and Applications
- Virus-based gene therapy research
- Colorectal Cancer Treatments and Studies
Integrated BioTherapeutics (United States)
2021-2025
Chinese University of Hong Kong
2011
766 Background: BASECAMP-1 (NCT04981119) is a pre-screening study to identify patients with tumor-associated human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH) for interventional studies, such as EVEREST-2 (NCT06051695), phase 1/2 logic-gated chimeric receptor T-cell (CAR T) therapy MSLN-expressing cancers. MSLN cell surface protein expressed in several cancer types, including mesothelioma (MESO), colorectal (CRC), non-small lung (NSCLC), ovarian (OVCA), and pancreatic (PANC)...
TPS2698 Background: Chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors are challenging due to a lack of tumor-specific targets that discriminate cancer from normal cells. Previous studies using CEA receptors and engagers have resulted in dose-limiting, on-target, off-tumor toxicities (1,2). A2B530 is an autologous logic-gated, CEA-targeted Tmod CAR therapy addresses the challenges toxicity by combining CAR-activating with blocking tumor cells (3). The activator...
Abstract In recent years, HER3 has increasingly been implicated in the progression of a variety tumor types and acquired resistance to EGFR HER2 therapies. Whereas primarily signal through MAPK pathway, HER3, as heterodimer with or HER2, potently activates PI3K pathway. Despite its critical role, previous attempts target neutralizing antibodies have shown disappointing efficacy clinic, most likely due suboptimal indirect mechanisms action that fail completely block heterodimerization; for...
190 Background: Metastatic colorectal (CRC), pancreatic (PANC), and gastroesophageal (GE) cancers are the leading causes of GI cancer–related mortality (5-yr survival rate, 14%, 3% ̃5-6%, respectively). T-cell immunotherapy targeting GI-associated tumor antigens has been attempted, but efficacy constrained by on-target off-tumor toxicity, limiting therapeutic window. The Tmod (TM) platform is an AND-NOT logic-gated CAR T modular system, versions which have a CEA- or MSLN-targeting activator...
1604 Background: Diversity in clinical studies is essential to address health disparities, but racial and ethnic minorities are often underrepresented studies, especially precision medicine using genetic data (1). BASECAMP-1 (NCT04981119) an ongoing prescreening study identify patients with unresectable advanced or metastatic solid tumors tumor-associated HLA-A*02 LOH for the EVEREST-1 -2 Tmod chimeric antigen receptor T-cell therapy trials. When enrollment began 2021, eligibility Part 1 was...
TPS2676 Background: Solid tumors comprise > 90% of cancers. Metastatic colorectal cancer, non-small cell lung and pancreatic cancer are among the leading causes cancer-related mortality (5-year overall survival: 14%, 6%, 3%, respectively) (ACS. 2021). Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies (Neelapu S. et al. N Engl J Med. 2017). Translating engineered therapies to solid proven be challenging due a lack tumor-specific...
<h3>Background</h3> Mesothelin (MSLN) is expressed on a variety of solid tumors, including mesothelioma and ovarian, uterine, gastric, pancreatic, lung cancers.<sup>1</sup> However, efforts to target MSLN using cellular therapies have been hampered by severe on-target, off-tumor toxicities associated with damage normal tissues expressing MSLN.<sup>2</sup> To avoid these toxicities, we developed logic-gated engineered cell therapy, Tmod™, which composed two chimeric antigen receptors (CARs):...
<h3>Background</h3> Solid tumors comprise >90% of cancers. Metastatic colorectal cancer, non-small cell lung and pancreatic cancer are among the leading causes cancer-related mortality (5-year overall survival: 14%, 6%, 3%, respectively).<sup>1</sup>Chimeric antigen receptor (CAR) T-cell therapy demonstrated clinical outcomes in hematologic malignancies.<sup>2 3</sup> However, translating engineered therapies to solid proves difficult due a lack tumor-specific targets that discriminate...
209 Background: Metastatic colorectal (CRC), pancreatic (PANC), and gastroesophageal cancers are the leading causes of GI cancer–related mortality (5-y survival: 15%, 3%, 5%-6%, respectively) (ACS 2022). HLA LOH is a recurrent mechanism immune escape observed in 15%-20% (Hecht R., ASCO The Tmod platform logic-gated chimeric antigen receptor (CAR) T-cell modular system, comprising carcinoembryonic (CEA)- or mesothelin (MSLN)-targeting CAR activator separate HLA-A*02-targeting blocker...